ClinicalTrials.gg

Program

Adjuvant

Also written as “Monovalent Avian Influenza VLP (H5N1); Adjuvant”, “Matrix-M2 Adjuvant (25μg)” and “Matrix-M2 Adjuvant (50μg)”.

Its studies are mostly in Influenza, Human · Herpes Simplex · Herpes Zoster · Malaria · Respiratory Syncytial Virus Infections, led by 11 companies.

Furthest: phase 2, since Apr 11, 201415 company-led studies, 3 open or runningNext primary completion: Jan 22, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genocea Biosciences30 open or runningphase 2since Apr 11, 2014Nov 19, 2013none ahead
BioTech Tools20 open or runningphase 2since Dec 7, 2011Apr 20, 2010none ahead
Novavax20 open or runningphase 1since May 2, 2012May 2, 2012none ahead
colby-pharmaceutical-company10 open or runningphase 1since Apr 15, 2008Apr 15, 2008none ahead
Guangzhou Patronus Biotech11 open or runningphase 1since May 28, 2024May 28, 2024none ahead
Immune Targeting Systems10 open or runningphase 1since Oct 3, 2012Oct 3, 2012none ahead
MAXVAX Biotechnology Limited Liability10 open or runningphase 1since Nov 16, 2022Nov 16, 2022none ahead
Medigen Vaccine Biologics10 open or runningphase 2since Apr 27, 2015Apr 27, 2015none ahead
Sanofi10 open or runningphase 1since Jun 25, 2020Jun 25, 2020none ahead
Serum Institute of India Pvt.11 open or runningphase 2since Aug 12, 2025Aug 12, 2025Nov 2027phase 2 · NCT07147400
Yikang Biotech (Suzhou)11 open or runningphase 1since Sep 1, 2026Sep 1, 2026Jan 22, 2027phase 1 · NCT07807449

Also a collaborator on its studies: yantai-patronus-biotech-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 15, 2008First study: phase 1 study in Influenza, HumanNew to colby-pharmaceutical-companycolby-pharmaceutical-company · NCT00662272 · 128 enrolled · United States
  2. Apr 20, 2010BioTech Tools's first study: phase 1 study in Seasonal Allergic RhinoconjunctivitisNew to BioTech ToolsBioTech Tools · NCT01111279 · 27 enrolled · Belgium
  3. Dec 7, 2011Phase 2 study in Rhinitis, Allergic, SeasonalBioTech Tools · NCT01506375 · 24 enrolled · Belgium
  4. May 2, 2012Novavax's first studies: 2 phase 1 studies in Influenza, HumanNew to NovavaxNovavax · NCT01594320, NCT01596725
  5. Oct 3, 2012Immune Targeting Systems's first study: phase 1 study in Influenza ANew to Immune Targeting SystemsImmune Targeting Systems · NCT01701752 · 120 enrolled
  6. Nov 19, 2013Genocea Biosciences's first study: phase 1 study in Streptococcus PneumoniaeNew to Genocea BiosciencesGenocea Biosciences · NCT01995617 · 90 enrolled · United States
  7. Apr 11, 2014Phase 2 study in Herpes SimplexGenocea Biosciences · NCT02114060 · 310 enrolled · United States
  8. Nov 20, 2014Phase 2 study in Herpes SimplexGenocea Biosciences · NCT02300142 · 37 enrolled · United States
  9. Apr 27, 2015Medigen Vaccine Biologics's first study: phase 2 study in H7N9 Influenza VaccineNew to Medigen Vaccine BiologicsMedigen Vaccine Biologics · NCT02436928 · 200 enrolled · Taiwan
  10. Jun 25, 2020Sanofi's first study: phase 1 study in Influenza, HumanNew to SanofiSanofi · NCT04451954 · 210 enrolled · United States
  11. Nov 16, 2022MAXVAX Biotechnology Limited Liability's first study: phase 1 study in Herpes ZosterNew to MAXVAX Biotechnology Limited LiabilityMAXVAX Biotechnology Limited Liability · NCT05636436 · 132 enrolled · China
  12. May 28, 2024Guangzhou Patronus Biotech's first study: phase 1 study in Respiratory Syncytial Virus InfectionsNew to Guangzhou Patronus BiotechGuangzhou Patronus Biotech · NCT06442241 · 84 enrolled · Australia
  13. Aug 12, 2025Serum Institute of India Pvt.'s first study: phase 2 study in Prevention of Malaria Transmission and Clinical MalariaNew to Serum Institute of India Pvt.Serum Institute of India Pvt. · NCT07147400 · 1,200 enrolled · Mali
  14. Sep 1, 2026Yikang Biotech (Suzhou)'s first study: phase 1 study in Respiratory Syncytial Virus (RSV)New to Yikang Biotech (Suzhou)Yikang Biotech (Suzhou) · NCT07807449 · 128 planned · China

Ahead

  1. Jan 22, 2027Primary completion: phase 1 study in Respiratory Syncytial Virus (RSV)Yikang Biotech (Suzhou) · NCT07807449
  2. Nov 2027Primary completion: phase 2 study in Prevention of Malaria Transmission and Clinical MalariaSerum Institute of India Pvt. · NCT07147400

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07807449Respiratory Syncytial Virus (RSV) · China1Not yet recruitingYikang Biotech (Suzhou)Jan 22, 2027128
NCT07147400Prevention of Malaria Transmission and Clinical Malaria · Mali2Active, not recruitingSerum Institute of India Pvt.Nov 20271,200
NCT06442241Respiratory Syncytial Virus Infections · Australia1Active, not recruitingGuangzhou Patronus BiotechDec 30, 202584
NCT05636436Herpes Zoster · China1CompletedMAXVAX Biotechnology Limited LiabilityMay 23, 2025132
NCT04451954Influenza, Human · United States1CompletedSanofiSep 20, 2021210
NCT02436928H7N9 Influenza Vaccine · Taiwan2CompletedMedigen Vaccine BiologicsFeb 2016200
NCT02300142Herpes Simplex · United States2CompletedGenocea BiosciencesJun 201637
NCT02114060Herpes Simplex · United States2CompletedGenocea BiosciencesFeb 2016310
NCT01995617Streptococcus Pneumoniae · United States1CompletedGenocea BiosciencesFeb 201590
NCT01701752Influenza A1CompletedImmune Targeting SystemsApr 2013120
NCT01596725Influenza, Human · United States1CompletedNovavaxAug 2012333
NCT01594320Influenza, Human · United States1CompletedNovavaxJul 2012333
NCT01506375Rhinitis, Allergic, Seasonal · Belgium2CompletedBioTech ToolsJan 201324
NCT01111279Seasonal Allergic Rhinoconjunctivitis · Belgium1CompletedBioTech ToolsSep 201027
NCT00662272Influenza, Human · United States1Completedcolby-pharmaceutical-companyOct 2008128

How it is read

Names in the registry

  • “Monovalent Avian Influenza VLP (H5N1); Adjuvant”, 6 entries
  • “Matrix-M2 Adjuvant (25μg)”, 2 entries
  • “Matrix-M2 Adjuvant (50μg)”, 2 entries
  • “Matrix-M2 Adjuvant (75μg)”, 2 entries
  • “Low dose adjuvant”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.